Kornimate/medical-research-clean huggingface dataset:
markers of atrial fibrillation

Conditions: Stroke; Atrial Fibrillation

Summary: this study will evaluate whether a gene marker can improve the identification of atrial fibrillation in patients with ischemic stroke, and evaluate whether the decision to anticoagulate could be improved by a marker of atrial fibrillation.

atrial fibrillation (af) is a major cause of ischemic stroke that is critical to identify because anticoagulation provides a 66% risk reduction in recurrent stroke. however, opportunities to prevent stroke due to af are frequently missed because af is paroxysmal and therefore not detected at the time of stroke. in addition, even when af is identified anticoagulation may not be initiated due to perceived contraindications. this study will (1) evaluate whether a gene marker can improve the identification of af in patients with ischemic stroke, and (2) evaluate decisions by health care provider and patients to anticoagulate af, and whether this decision could be improved by a marker of af at time of stroke. an af gene score will be developed comprised of genes associated with inflammatory and thrombotic pathways related to risk of af thromboembolism in stroke patients with af. the af gene score measured at time of stroke can stroke will permits rapid identification of stroke due to af which may increase initiation of anticoagulation therapy. this is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty regarding the association of delayed af with initial stroke and delays anticoagulation.

Eligibility criteria:
inclusion criteria: * ischemic stroke within 72 hours of onset * complete evaluation to determine cause of stroke * informed consent exclusion criteria: * active infection * lymphoma / leukemia / blood dyscrasia * hemorrhagic stroke * immunosuppressive therapy * illicit drug use * blood transfusion +/- 1 month * major surgery/trauma in last 6mts
cohort of non-small cell lung cancer with mutation of the nord pas de calais (cb(npc)²)

Conditions: Non-Small Cell Lung Cancer

Summary: the investigators propose to create a database at the regional level, the principle is to include all patients in whom a mutation was detected from a single platform (lille). the creation of this regional cohort, smaller than the national cohort of biomarkers france, will perform a more comprehensive collection of clinical data, and molecular monitoring data of patients included. to increase the completeness of the collection of information, it will not be based on voluntary prescribing clinician but will be largely carried out by cra dedicated to this activity.

this is a prospective and retrospective study of a population of patients with mutated non-small cell lung cancer in the nord pas de calais. retrospective cohort will involve patients with main molecular abnormalities, identifiable from molecular biology platform crrc, except egfr and kras treated from september 2011 to february 2013.

Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * patient with non-small cell lung cancer * detected in the nord pas de calais * monitored in the nord pas de calais * patient must have signed a non-opposition form to the use of medical data exclusion criteria: - no identified mutation

Keywords: mutation
caries location and its effect on the success rate of indirect pulp treatment in primary molars

Conditions: Deep Caries Lesion of Primary Teeth; Dental Pulp Diseases; Deep Proximal Caries; Deep Occlusal Caries; Reversible Pulpitis; Pulpitis; Decayed Teeth

Summary: the following study will be created to evaluate how the location of caries affects the effectiveness of indirect pulp treatment in primary molars. aiding in the development of evidence-based recommendations for pediatric dentists.

a selective case study design will be employed, focusing on primary molars with either occlusal or proximal carious lesions. children aged between 3 to 7 years meeting the inclusion criteria will be examined clinically and radiographically to assess the extent and location of the carious lesion. two groups will be involved in the study; primary molars will be submitted to each group based on whether the lesion is proximal or occlusal. both groups will then receive indirect pulp therapy, and a clinical and radiographic evaluation for one year will be conducted. the purpose of this study is to examine how the location of caries, whether proximal or occlusal, affects the success rate of ipt in primary molars. understanding this relationship is essential for developing more tailored clinical approaches in pediatric dentistry to ensure long-term treatment success.

Eligibility criteria:
inclusion criteria: * participant criteria: 1. children aged between 3-7 years 2. children in complete physical and mental health. 3. children with free medical history. 4. patient with favorable attitudes, which will be assessed by using frankl behavior rating. teeth criteria: 1. primary molars with active occlusal or proximal deep caries. 2. teeth with reversible pulpitis 3. asymptomatic teeth or teeth with provoked pain of short duration 4. teeth should be restorable. exclusion criteria: * clinical signs or symptoms suggesting evidence of pulp degeneration or a non -vital tooth such as: * clinical symptoms or history indicating irreversible pulpitis as (spontaneous pain, throbbing pain). * tenderness to percussion. * soft tissue swelling, abscess, draining fistula or sinus tracts. * pathological tooth mobility. presence of the following radiographic criteria: * periapical or inter-radicular radiolucency. * internal or external pathological root resorption. * furcation involvement * widening of periodontal space.

Keywords: indirect pulp treatment ipt caries location caries site proximal and occlusal caries proximal caries occlusal caries pulp therapy reversible pulpitis pulpitis deciduous teeth caries in milk teeth
web-based education on oral cancer for primary care physicians in ohio

Conditions: Oral Cancer

Summary: objective: the experimental design is a one-site, randomized experimental web-based educational feasibility intervention trial, with approximately 50% primary care physicians (pcps) in the intervention group and approximately 50% pcps on the control group, giving a total of 159 participants. all 159 participants have willingly provided their e-mail addresses, as part of a survey they previously completed entitled, "survey of health professionals on oral cancer in ohio- intervention to prevent delayed diagnosis of oral cancer."

the main specific aim is to determine the short-term effectiveness of a web-based educational intervention for primary care physicians (pcps) in ohio to improve the following:index of knowledge of risk factors for oral cancer, and index of knowledge of diagnostic procedures for oral cancer the following hypothesis will be explored: the use of a web-based educational module for pcps in ohio regarding oral cancer will increase the proportion of the pcps in the high score category for the following indices: index of knowledge of risk factors of oral cancer, and index of knowledge of diagnostic procedures for oral cancer

Eligibility criteria:
inclusion criteria: * the pcp's who participated in specific aim #2 (survey of healthcare professionals on oral cancer in ohio ) of the nih k23 grant proposal, "intervention to prevent delayed diagnosis of oral cancer", will be eligible to participate in this web-based education on oral cancer. * possessing the ability to give voluntary consent to participate. participating in the web-based educational intervention is am implication of consent. * all participants are expected to be relatively healthy. exclusion criteria: • unable to have access to the internet to be able to participate in the web-based education.
trazodone for sleep disorders in alzheimer's disease

Conditions: Sleep; Sleep Disorders; Insomnia; Alzheimer's Disease

Summary: the purpose of this study is to determine whether trazodone is effective in the treatment of sleep disorders in alzheimer's disease (ad).

sleep disorders (sd) affects 35 to 50 percent of patients with ad. these disorders often make caring for patients at home very difficult. trazodone is commonly prescribed drugs for sd in ad patients. there are no controlled studies in this sample of patients for this purpose.

Eligibility criteria:
inclusion criteria: * fifty-five years of age or older; * diagnosis of probable alzheimer's disease by national institute of neurological and communicative disorders and stroke/the alzheimer's disease and related disorders association criteria; * hachinski ischemia scale score less than 5 * mini-mental state examination score of o to 26 * actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week; * for-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the neuropsychiatric inventory (npi) nighttime behavior scale; * sleep disturbance observed was not present before the diagnosis of ad; * other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms; * computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal; * stable medications for 4 weeks prior to the screening visit; * having a mobile upper extremity to which to attach an actigraph; * residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principal caregiver for the 3-week protocol; * ability to ingest oral medication and participate in all scheduled evaluations exclusion criteria: * sleep disturbance associated with an acute illness, delirium or psychiatric disease; * clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness * severe agitation; * unstable medical condition; * discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit; * patient unwilling to maintain caffeine abstinence after 2:00 pm for the duration of the protocol; * patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00 pm for the duration of the protocol; * prior use of trazodone for the treatment of sleep disturbances; * caregiver deemed too unreliable to supervise the wearing of the actigraph, to administer trazodone the proper time, to maintain tbe sleep diary, or to bring the patient to the scheduled visits;

Keywords: sleep disturbances alzheimer disease insomnia trazodone treatment
peer coaching intervention in young adults with congenital heart disease

Conditions: Congenital Heart Disease; Congenital Heart Defect

Summary: the purpose of the study is to evaluate a peer coaching intervention in young adults with congenital heart disease.

our research team has developed a peer coaching intervention that has been deployed to promote activated self-management for ayas with several conditions, and this has been modified adolescents and young adults (aya) with with congenital heart disease (chd). this study will be conducted over two years and pair aya with chd with a peer coach who also has chd has successfully navigated the transition to adult medical care and over six months will work to promote the motivation for self-care as well as the development of self-management skills. this pilot study will test feasibility and acceptability, as well as preliminary efficacy and long-term effects on successful transfer to adult cardiology.

Eligibility criteria:
inclusion criteria: * age 18-26 * diagnosis of congenital heart disease * patient at a duke pediatric cardiology clinic * access to a smart phone exclusion criteria: * cognitive delay * patient at an adult cardiology clinic
excimer lamp versus excimer laser in vitiligo treatment

Conditions: Vitiligo

Summary: 308 nm excimer lamp and 308 nm excimer laser have both provide interesting results in treating vitiligo. they have the same wavelength but the type of emission of the photons is different. to date there is no direct comparative data concerning these two devices in this indication. the aim of the study is to make an intra-individual prospective comparison between these two phototherapies.


Eligibility criteria:
inclusion criteria: * patient above 18 * vitiligo for more than 3 months * at least 2 vitiligo symmetric patches more than 10cm² * to read and understand the inform consent * to have a social security number * non pregnant for women exclusion criteria: * pregnant women * keloids * history of radiotherapy or skin cancer in the treated areas * treatment for vitiligo in the past 4 weeks * phototherapy in the past 12 weeks; history of photodermatosis * treatment inducing photosensibilization * immunosuppression * patient who participated in a study in the past 3 months

Keywords: vitiligo
escitalopram in the treatment of adolescents with major depressive disorder or anxiety disorders

Conditions: Major Depressive Disorder; Anxiety Disorders

Summary: escitalopram has been approved by fda in the treatment of adolescents with major depressive disorder since march 2009. to date, there are only 3 clinical trials assessing the effect and validity of escitalopram on major depressive disorder, which of them has resulted in inconsistent findings. in the present study, the authors aimed to assess the effect and validity of this drug in the treatment of adolescents with major depressive disorder and or anxiety disorders.

escitalopram has been approved by fda in the treatment of adolescents with major depressive disorder since march 2009. although wagner and colleagues reported that escitalopram has a tendency toward positive findings for the treatment of pediatric patients with major depressive disorder in their study it was found that this effect has not reached a statistical significance. noteworthy the authors reported statistical significance for escitalopram when they only included adolescent subgroup into further analysis. however, there are also clinical trials in the literature reporting the effectiveness of escitalopram on adolescence major depressive disorder (emslie, findling). it was indicated that no serious adverse effect of escitalopram was reported in these studies comparing escitalopram with placebo. in this study the authors aimed to investigate the effect and reliability of the drug in the treatment of adolescents with major depressive disorder and/or anxiety disorders. additionally, cognitive behavioral therapy and ssris are indicated for the first-line treatment of anxiety disorders. the authors included escitalopram for the treatment of pediatric anxiety disorders.

Eligibility criteria:
inclusion criteria: * drug-naive * being in the age range of 12-18 * lack of any psychiatric comorbidity, except for adhd-like problems during the illness * iq level\> 80 * lack of history of any major medical disease, substance abuse exclusion criteria: * inappropriate age * history of drug abuse, major medical disease * mental retardation * any psychotropic drug use * hospitalization required for suicidal ideation/behavior

Keywords: major depressive disorder anxiety disorders adolescent child
cmp vs fascia iliaca block

Conditions: Pain, Postoperative; Hip Arthroplasty

Summary: complete motorsparing protocol (cmp) has been developed to try to minimize the motor nerve block that is created when using facia iliaca nerve block. the blocks performed in the (cmp) are the cluneal nerve block, pericapsular nerve group block and lateral femoral cutaneous block. on the clinical trial, the investigators will randomize the participants that meet criteria to cmp or fascia iliaca block and compare the amount of opioid needed post op during 24 hours and their pain scores.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old * patients undergoing total hip arthroplasty posterior approach. * patients willing to participate and sign informed consent exclusion criteria: * severe copd/other contraindication to general anesthesia that spinal would be more suitable. * patient with a weight of less than 41 kg * dementia, not alert or oriented to person, place, or time * chronic pain patient with daily opioid use at home. * patient with allergy to local anesthetics * patient refusal * total hip arthroplasty revision * concomitant pain in different area from operative site. * pregnancy * patient with active infection on the injection sites for the blocks * patients unable or willing to understand or comply with the study protocol

Keywords: nerve block fascia iliaca nerve block complete motor sparing protocol hip arthroplasty pain control
rituximab for anca-associated vasculitis (rave) long-term follow-up study

Conditions: Granulomatosis With Polyangiitis; Microscopic Polyangiitis

Summary: rituximab is the first drug approved by the united states food and drug administration (fda) for the treatment of patients with granulomatosis with polyangiitis (wegener's granulomatosis) or microscopic polyangiitis. because it is a relatively new medication, the long-term safety and efficacy of this drug is not yet clear. this study proposes to follow patients who were enrolled in the rave study to determine if treatment with rituximab influences long-term outcomes.


Eligibility criteria:
inclusion criteria: 1. enrollment in the rave trial 2. completion of rave common closeout date visit 3. informed consent exclusion criteria: 1. refusal to participate 2. inability to comply with standard-of-care, including routine clinical visits and testing.

Keywords: vasculitis anca rituximab small vessel vasculitis
study on multimodal imaging and molecular imaging techniques in degenerative dementia

Conditions: Alzheimer Disease; Image

Summary: this project is a multicenter observational study that establishes a longitudinal cohort of patients with alzheimer's disease and other dementias based on neuroimaging, molecular imaging, biological and digital markers to explore new solutions such as dementia disease mechanism, diagnosis, condition evaluation, and prognosis assessment.

this project will build a longitudinal database based on multimodal mri imaging information of dementia subjects, various body fluid or digital markers, and a cohort. the convolutional neural network algorithm will be used to explore the imaging characteristics of healthy controls, ad, ftd, and dlb, develop an early prediction model for degenerative dementia, and achieve early differential diagnosis of different dementia subtypes. this study further performed ge180, asem, and exendin-4 radionuclide imaging on some subjects who completed conventional pet (av45, tauvir, and fdg) imaging to explore the diagnostic efficacy of these three probes as new diagnostic probes for early ad. in addition, through longitudinal follow-up of aβ-positive mci patients, multimodal mri and pet image fusion technology were used to explore the changes in fused images during their conversion to ad in order to obtain early and accurate diagnostic markers.

Eligibility criteria:
inclusion criteria: * patients aged ≥50 and ≤85 years old, male or female; * meet the diagnostic criteria for dementia or mci; * neuropsychological score: mmse 15-28 points, cdr ≤ 1 point; ④ patients and their families are informed and sign the informed consent form exclusion criteria: * the presence of other neurological diseases that may cause brain dysfunction (such as depression, brain tumors, parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.); * the presence of other systemic diseases that may cause cognitive impairment (such as liver dysfunction, renal dysfunction, thyroid dysfunction, severe anemia, folic acid or vitamin b12 deficiency, syphilis, hiv infection, alcohol and drug abuse, etc.); * suffering from a disease that makes it impossible to cooperate with cognitive examinations; * the presence of contraindications to mri; * the presence of mental and neurological retardation; * refusing to draw blood; * refusing to sign the informed consent form.

Keywords: alzheimer disease molecular imaging
treatment of severe heart failure by ultrafiltration

Conditions: Severe Congestive Heart Failure

Summary: patients with severe congestive heart failure show increased fluid body content which is often resistant to conventional diuretic therapy. therefore, chronic heart failure patients have frequent access to the emergency room and hospital for hemodynamic instability. ultrafiltration is a simple renal replacement therapy which reduces fluid overload. the purpose of this study is to determine whether periodic ultrafiltration sessions maintain patients in stable clinical condition and reduce hospitalisations as well as access to emergency heart failure treatment.

patients with severe heart failure (new york heart association \[nyha\] iii-iv) and fluid overload will be randomized to ultrafiltration (uf group) or conventional medical treatment (control group). patients follow-up at least monthly visit for one year. ultrafiltration will be repeated during follow-up in case of body weight gain due to fluid accumulation. ultrafiltration will be performed during short term hospitalization.

Eligibility criteria:
inclusion criteria: * severe heart failure (nyha iii-iv) with fluid overload * ejection fraction \< 40% * estimated fluid overload \> 4 kg exclusion criteria: * severe renal insufficiency * acute pulmonary edema and/or cardiogenic shock

Keywords: ultrafiltration heart failure fluid overload